J. Miguel, L. H. Araujo, and R. Costa, “Cost-effectiveness of erlotinib compared to gefitinib for NSCLC with EGFR mutations at the Inca”, JBES, vol. 12, no. 1, pp. 8–15, Apr. 2020.